Investment Rating - The report maintains a "Recommended" rating for the company [3][5]. Core Views - The company's revenue for H1 2025 was 3.03 billion yuan, a year-on-year decrease of 13.87%, with a net profit attributable to shareholders of 111 million yuan, down 27.60% year-on-year [1]. - The decline in performance is attributed to fluctuations in raw material prices and weak downstream demand, particularly in Q2 2025, where revenue dropped to 1.47 billion yuan, a 21.93% year-on-year decrease [2]. - Despite short-term pressures, the long-term outlook remains positive due to the company's high-end positioning in the nylon chip market and ongoing capacity expansions [2]. Summary by Sections Financial Performance - In H1 2025, the company reported a revenue of 3.03 billion yuan and a net profit of 111 million yuan, with a significant decline in Q2 performance [1]. - The average price of caprolactam in Q2 2025 was 9,193 yuan/ton, down 12.65% from Q1 [2]. - The company expects net profits to grow to 350 million yuan in 2025, 456 million yuan in 2026, and 553 million yuan in 2027, with corresponding PE ratios of 11, 9, and 7 [3][4]. Industry Outlook - The nylon chip industry is projected to reach a capacity of 8.5 million tons by the end of 2025, with a production of 7 million tons and demand of 6.4 million tons [2]. - The company has strategically positioned itself with production bases in multiple locations, enhancing its competitive edge in high-end nylon chips [2]. Investment Recommendations - The company has a strong foundation in nylon 6 polymerization technology and is expanding into nylon 66 products, which is expected to create a second growth curve [3]. - The report forecasts a revenue growth rate of 29.5% in 2025, followed by 26.0% in 2026 and 17.6% in 2027 [4][9].
聚合顺(605166):2025年半年报点评:25Q2利润短期承压,中长期核心主线奠基长期价值